<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="in particular IFN-Î², are promising drugs for SARS-CoV2 infection. â€¢Early" exact="infection" post="in elderly patients is the best setting to exploit"/>
 <result pre="deserves further clinical investigation. â€¢Attention should be paid to IFN-I" exact="treatment" post="in patients with severe COVID-19. Abstract Coronavirus disease 2019"/>
 <result pre="the lack of approved treatments for any human coronavirus (CoV)" exact="infection" post="highlight the urgent need to develop strategies to prevent"/>
 <result pre="viral diseases [10] and cancer (IFN-Î±) [11], and in the" exact="treatment" post="of relapsing-remitting multiple sclerosis (MS) (IFN-Î², [12]). Indeed, IFN-I"/>
 <result pre="antiviral activity of IFN-I has been extensively exploited for the" exact="treatment" post="of viral chronic infections [10]. Nevertheless, as highlighted by"/>
 <result pre="the IFN-I system and the dysregulated IFN-I response in SARS-CoV-2" exact="infection" post="point to the need of a fine-tuning of route,"/>
 <result pre="reduces IFN-I production by alveolar phagocytes in response to viral" exact="infection" post="[19]. Fig. 1 COVID-19 and IFN-I treatment. In the"/>
 <result pre="treatment. In the majority of patients (left panels) early phase" exact="infection" post="results in a physiological IFN-I activation that favors the"/>
 <result pre="effect. This immune activation leads to a resolution of the" exact="infection" post="without any need of treatment. Instead, approximately 15â€&quot;20 %"/>
 <result pre="This group of patients would strongly benefit of an IFN-I" exact="treatment" post="at the early phase of infection (right panels) as"/>
 <result pre="benefit of an IFN-I treatment at the early phase of" exact="infection" post="(right panels) as it would re-establish a functional immune"/>
 <result pre="infection. At bottom, diagrams summarizing the variation over time of" exact="infection" post="levels and immune response for each scenario. This figure"/>
 <result pre="mechanisms intervening in early stage versus late stage of SARS-CoV-2" exact="infection" post="(reviewed in [17]) and to the role of comorbidities"/>
 <result pre="and MERS-CoV, as well as the immunologic changes observed during" exact="infection" post="[23] point to a dysregulated IFN-I response in COVID-19"/>
 <result pre="disease and fatal outcomes in MERS patients [26]. Likewise, SARS-CoV-2" exact="infection" post="(either in cell lines, primary cell cultures, ferrets, and"/>
 <result pre="active, but delayed IFN-related antiviral responses to SARS-CoV and MERS-CoV" exact="infection" post="[29,30]. These results are in line with data on"/>
 <result pre="exogenous administration of IFN-Î² completely protected mice from lethal MERS-CoV" exact="infection" post="by inhibiting virus replication and inflammatory cytokine production, delayed"/>
 <result pre="[32]. In conclusion, in comparison to other respiratory viruses, SARS-CoV-2" exact="infection" post="drives a lower antiviral transcriptional response that is marked"/>
 <result pre="of NK, T and B cells at the site of" exact="infection" post="[38]. Notably, the interplay IFN-I/DC is crucial for the"/>
 <result pre="a significant antiviral immune response attenuating the severity of the" exact="infection" post="and protecting against subsequent viral challenge [43]. This evidence"/>
 <result pre="believe that IFN-I can represent not only a direct antiviral" exact="treatment" post="restricting early viral spread, but also a valuable tool"/>
 <result pre="tool to enhance humoral and cellular immunity, thus halting viral" exact="infection" post="from progressing towards a more severe form of disease."/>
 <result pre="The past experience on IFN-I in cancer and chronic viral" exact="infection" post="was mainly based on repeated intravenous (i.v.) or subcutaneous"/>
 <result pre="that the immunomodulation phenomena occurring upon IFN-Î± or Î² systemic" exact="treatment" post="may concur in the stimulation of pro-inflammatory cytokines in"/>
 <result pre="evidence available so far, the use of IFN-I for the" exact="treatment" post="of severe COVID-19 patients should be discouraged. 6 Mucosal"/>
 <result pre="increasing interest in developing mucosal treatments for either prevention or" exact="treatment" post="of COVID-19. The first attempts to deliver IFN-I to"/>
 <result pre="administration of IFN-Î± to medical staff at risk of SARS-CoV-2" exact="infection" post="results in complete protection [61]. Since the beneficial effects"/>
 <result pre="further studies are needed to confirm IFN-I efficacy against SARS-CoV-2" exact="infection" post="and to better characterize the biological activities, the mechanisms"/>
 <result pre="a mucosal delivery of IFN-I, besides being targeted at the" exact="infection" post="site, could be more compliant and less toxic than"/>
 <result pre="administration, especially for prophylaxis in subjects at high risk of" exact="infection" post="or in early phases of household management of infected"/>
 <result pre="use of these cytokines in patients with chronic hepatitis C" exact="infection" post="and cancer, has been suggested in some of the"/>
 <result pre="refractoriness recently underlined [11,45] and discussed above, we believe this" exact="treatment" post="schedule should be discouraged in favor of a discontinuous"/>
 <result pre="treatment schedule should be discouraged in favor of a discontinuous" exact="treatment" post="schedule. In the majority of the proposed studies, IFN-Î±"/>
 <result pre="moderate COVID-19 [64]. Notably, due to the absence of single" exact="treatment" post="arms in this clinical study, it cannot be discerned"/>
 <result pre="least in part, responsible for the spontaneous resolution of SARS-CoV-2" exact="infection" post="in the majority of infected patients (estimated around 80"/>
 <result pre="(2â€&quot;4 million per injection) at the earliest time of SARS-CoV-2" exact="diagnosis" post="(Fig. 1). Further research efforts should be dedicated to"/>
 <result pre="of the endogenous IFN-I signaling in the susceptibility to SARS-CoV-2" exact="infection" post="and in the progression to the severe forms of"/>
 <result pre="its multiple biological activities against COVID-19 pandemic, low-dose, intermittent IFN-I" exact="treatment" post="schedules should be used in the early stages of"/>
 <result pre="treatment schedules should be used in the early stages of" exact="infection" post="to compensate for virus-induced IFN-impairment or IFN-deficiency in the"/>
 <result pre="1HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.-M.YanW.-W.ChanW.-M.ChanJ.F.-W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
 <result pre="32ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Invest.12920193625363910.1172/JCI12636331355779 33Blanco-MeloD.Nilsson-PayantB.E.LiuW.C.UhlS.HoaglandD.MÃ¸llerR.JordanT.X.OishiK.PanisM.SachsD.WangT.T.SchwartzR.E.LimJ.K.AlbrechtR.A.B.R. tenOever, imbalanced host response to"/>
 <result pre="as regulators of lung inflammationFront. Immunol.8201725910.3389/fimmu.2017.0025928344581 54MeriganT.C.HallT.S.ReedS.E.TyrrellD.A.J.J.UnitM.R.C.C.C.HospitalH.Inhibition of respiratory virus" exact="infection" post="by locally applied InterferonLancet.301197356356710.1016/S0140-6736(73)90714-9 55VelkovT.Abdul RahimN.ZhouQ.T.ChanH.K.LiJ.Inhaled anti-infective chemotherapy for"/>
 <result pre="in an epidemic areaMedRxiv.202010.1101/2020.04.11.200614732020.04.11.20061473 62SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN.Type 1 interferons as a potential" exact="treatment" post="against COVID-19Antiviral Res.178202010479110.1016/j.antiviral.2020.10479132275914 63RossT.M.MartinezP.M.RennerJ.C.ThorneR.G.HansonL.R.FreyW.H.Intranasal administration of interferon beta bypasses"/>
 <result pre="the central nervous system and cervical lymph nodes: a non-invasive" exact="treatment" post="strategy for multiple sclerosisJ. Neuroimmunol.1512004667710.1016/j.jneuroim.2004.02.01115145605 64Fan-Ngai HungI.LungK.-C.Yuk-Keung TsoE.LiuR.Wai-Hin ChungT.ChuM.-Y.NgY.-Y.LoJ.ChanJ.W.Raymond"/>
 <result pre="ToK.YuenK.-Y.HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.W.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.W.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.YanW.-W.ChanW.-M.W.-M.ChanJ.W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
 <result pre="of systemic and mucosal type I Interferons in both influenza" exact="infection" post="as well as tumor models. The research activity is"/>
</results>
